(Q37230269)

English

A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India

scientific article published on February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Vidya Nand Rabi Das

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Niyamat Ali Siddiqui

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Krishna Pandey

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Vijay Pratap Singh

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Roshan K Topno

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Dharmendra Singh

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Rakesh Bihari Verma

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Alok Ranjan

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Prabhat Kumar Sinha

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Pradeep Das

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

1 February 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Therapeutics and Clinical Risk Management

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

117-124

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Drug policy for visceral leishmaniasis: a cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Visceral leishmaniasis - current therapeutic modalities.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Drug resistance in leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Practical progress and new drugs for changing patterns of leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Recent understanding in the treatment of visceral leishmaniasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Oral miltefosine for Indian visceral leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Clinical and experimental advances in treatment of visceral leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

The reemergence of visceral leishmaniasis in Brazil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

9 September 2017

A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

14 September 2017

A randomized comparison of classical mode of administration of amphotericin B with its newer modes of administration in kala-azar

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

14 September 2017

Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

14 September 2017

Amphotericin versus pentamidine in antimony-unresponsive kala-azar

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

28 September 2017

Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

26 June 2018

Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

3 September 2018

Risk factors for Indian kala-azar.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

3 September 2018

A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

3 September 2018

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

3 September 2018

A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

3 September 2018

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

3 September 2018

Treatment of visceral Leishmaniasis unresponsive to pentamidine with amphotericin B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

3 September 2018

Comparison of Regimes of Treatment of Antimony-Resistant Kala-Azar Patients: A Randomized Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697519

3 September 2018

[Visceral leishmaniasis resistant to conventional treatments: value of amphotericin B]

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of kala-azar during pregnancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37230269&oldid=2109092252"